Pleural
Phase 1/1b study of direct intratumoral injection of pleural mesothelioma of immunostimulant prior to surgical resection
The Journal of Thoracic & Cardiovascular Surgery 2026 March 24 [Link] Andrea S Wolf, Shubham Gulati, Komal Dolasia, Bailey Fitzgerald, Jorge Gomez, David Yankelevitz, Andres Salazar, Alexander M Tsankov, Thomas Marron, Raja Flores Abstract Objective: To evaluate the role of neoadjuvant injection of the viral mimic poly-ICLC (polyinosinic-polycytidylic acid-poly-l-lysine carboxymethylcellulose) in patients with pleural mesothelioma…
Read MorePhase 1/1b study of direct intratumoral injection of pleural mesothelioma of immunostimulant prior to surgical resection
The Journal of Thoracic and Cardiovascular Surgery 2026 March 24 [Link] Andrea S Wolf, Shubham Gulati, Komal Dolasia, Bailey Fitzgerald, Jorge Gomez, David Yankelevitz, Andres Salazar, Alexander M Tsankov, Thomas Marron, Raja Flores Abstract Objective: To evaluate the role of neoadjuvant injection of the viral mimic poly-ICLC (polyinosinic-polycytidylic acid-poly-l-lysine carboxymethylcellulose) in patients with pleural mesothelioma…
Read MoreCase Report: Immune checkpoint inhibitor-triggered anti-Ma2 paraneoplastic encephalitis in sarcomatoid pleural mesothelioma: a fatal case
Frontiers in Oncology 2026 March 9 [Link] Ilker Nihat Okten, Tuba Baydaş Abstract Background: Neurological immune-related adverse events (N-irAEs) represent rare but potentially fatal complications of immune checkpoint inhibitor (ICI) therapy. Among these, encephalitis associated with paraneoplatic neuronal antibodies poses a major diagnostic and therapeutic challenge, as it blurs the distinction between drug-induced toxicity and…
Read MoreCytoreductive Surgery With or Without HITHOC for Pleural Mesothelioma: A Meta-analysis of Survival and Perioperative Outcomes
Annals of Surgical Oncology 2026 March 16 [Link] Lucas Monteiro Delgado, Rachid Eduardo Noleto da Nobrega Oliveira, Guilherme Franceschini Machado, Luiza Soares Guerra, Cauã de Toledo Corrêa, Mario Claudio Ghefter, Paulo Manuel-Pêgo Fernandes, Marcello Migliore, Ricardo Mingarini Terra, Paula Duarte D’Ambrosio Abstract Background: Pleural mesothelioma (PM) is a rare and aggressive malignancy with limited overall…
Read MoreTGF-β Inhibition Through Combinatory Strategies Suppresses Proliferation and Invasiveness in Malignant Pleural Mesothelioma
International Journal of Molecular Sciences 2026 February 25 [Link] Valeria Ramundo, Maria Luisa Palazzo, Stefania Lignola, Daniela Raimondo, Joanna Kopecka, Elisabetta Aldieri Abstract Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor associated with asbestos exposure, which represents a current problem. MPM is characterized by a poor prognosis and an unsatisfactory therapeutic approach. Therefore,…
Read MorePivotal role of long non-coding RNA in the development of new therapeutic approaches for pleural mesothelioma
Discover Oncology 2026 March 12 [Link] Caroline Joseph Kiriacos, Dina M Elkahwagy, Manar Mansour Abstract Pleural mesothelioma is a rare aggressive tumor that affects the parietal layer of the pleura. It constitutes 90% of mesotheliomas. Usually, the diagnosis takes place 30 to 40 years after asbestos exposure. Thus, patients are diagnosed at a very late…
Read MoreMalignant Pleural Mesothelioma (MPM) Evaluation with [11C]-Methionine PET/CT Before and After Talc Pleurodesis
Molecular Imaging and Biology 2026 March 9 [Link] Egesta Lopci, Angelo Castello, Alberto Testori, Emanuele Voulaz, Daoud Rahal 5, Matteo Perrino 6, Alessandro Crepaldi 3, Giorgio Maria Ferraroli 3, Valentina Errico 3, Edoardo Bottoni 3, Marcello Rodari 7, Lorenzo Muraglia 2, Giuseppe Marulli 3 4, Marco Alloisio, Paolo Andrea Zucali Abstract Background: Malignant pleural mesothelioma…
Read MoreGermline genetic testing and privacy concerns in patients with mesothelioma
Genetics in Medicine 2026 March 4 [Link] Owen D Mitchell, Abigail P Sneider, Katie Gilliam, Daniela Del Gaudio, Meghana Gaduraju, Soma Das, Feighanne Hathaway, Darren S Bryan, Sanjukta Tawde, Shelly Galasinski, John Novembre, Anya E R Prince, Jane E Churpek, Hedy L Kindler, Michael W Drazer Abstract Purpose: Mesothelioma, a disease overwhelmingly driven by asbestos…
Read MoreEnhanced nuclear export caused by O-GlcNAcylation of nucleoporins is a potential therapeutic target in mesothelioma
British Journal of Cancer 2026 May [Link] Satomi Mukai, Tatsuhiro Sato, Yasuhiro Kamei, Kagayaki Kato, Emi Mishiro-Sato, Lisa Kondo-Ida, Norikazu Yabuta, Kenzo Hiroshima, Yoshitaka Sekido Abstract Background: Mesothelioma is an aggressive malignancy with limited therapeutic options. Genetic alterations involving the Hippo pathway are commonly observed. O-GlcNAcylation is frequently elevated in cancer and drives tumour progression.…
Read MoreAdvancing Rare Cancer Therapeutics: Osimertinib-Loaded Inhaled PLGA Nanoparticles for Mesothelioma Treatment
AAPS PharmSciTech 2026 March 4 [Link] Mural Quadros, Naveen Rajana, Vivek Gupta Abstract Despite advances in mesothelioma treatment, malignant pleural mesothelioma (MPM) continues to present a poor prognosis due to its aggressive progression and resistance to conventional therapies. Current treatment modalities, including surgery, chemotherapy, radiation, and immunotherapy, offer limited efficacy, with a five-year survival rate…
Read More
Skip to content